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Abstract
The inability of sodium antimony gluconate (SAG)-unresponsive kala-azar patients to clear Leishmania donovani (LD)
infection despite SAG therapy is partly due to an ill-defined immune-dysfunction. Since dendritic cells (DCs) typically initiate
anti-leishmanial immunity, a role for DCs in aberrant LD clearance was investigated. Accordingly, regulation of SAG-induced
activation of murine DCs following infection with LD isolates exhibiting two distinct phenotypes such as antimony-resistant
(Sb
RLD) and antimony-sensitive (Sb
SLD) was compared in vitro. Unlike Sb
SLD, infection of DCs with Sb
RLD induced more IL-
10 production and inhibited SAG-induced secretion of proinflammatory cytokines, up-regulation of co-stimulatory
molecules and leishmanicidal effects. Sb
RLD inhibited these effects of SAG by blocking activation of PI3K/AKT and NF-kB
pathways. In contrast, Sb
SLD failed to block activation of SAG (20 mg/ml)-induced PI3K/AKT pathway; which continued to
stimulate NF-kB signaling, induce leishmanicidal effects and promote DC activation. Notably, prolonged incubation of DCs
with Sb
SLD also inhibited SAG (20 mg/ml)-induced activation of PI3K/AKT and NF-kB pathways and leishmanicidal effects,
which was restored by increasing the dose of SAG to 40 mg/ml. In contrast, Sb
RLD inhibited these SAG-induced events
regardless of duration of DC exposure to Sb
RLD or dose of SAG. Interestingly, the inhibitory effects of isogenic Sb
SLD
expressing ATP-binding cassette (ABC) transporter MRPA on SAG-induced leishmanicidal effects mimicked that of Sb
RLD to
some extent, although antimony resistance in clinical LD isolates is known to be multifactorial. Furthermore, NF-kB was
found to transcriptionally regulate expression of murine cglutamylcysteine synthetase heavy-chain (mcGCShc) gene,
presumably an important regulator of antimony resistance. Importantly, Sb
RLD but not Sb
SLD blocked SAG-induced mcGCS
expression in DCs by preventing NF-kB binding to the mcGCShc promoter. Our findings demonstrate that Sb
RLD but not
Sb
SLD prevents SAG-induced DC activation by suppressing a PI3K-dependent NF-kB pathway and provide the evidence for
differential host-pathogen interaction mediated by Sb
RLD and Sb
SLD.
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Introduction
Kala-azar, caused by Leishmania donovani (LD), is regarded as the
most severe form of leishmanial infection, which can be fatal in
patients when left untreated. In the absence of an effective vaccine,
treatment with pentavalent antimonial compounds such as sodium
antimony gluconate (SAG) remains as the first-choice therapy for
kala-azar. However, therapeutic utility of SAG is now jeopardized
by the emergence of antimony-resistant strains of LD [1], which is
becoming a major concern of the World Health Organization
(www.who.int/infections-disease-report/2000).
Resistance to antimonial drugs, as observed in leishmanial
infection, is marked by two independent ‘‘checkpoints’’. The first is
associated with the impaired biological reduction of the pentava-
lent antimony (Sb
V) prodrug to a toxic trivalent (Sb
III) form,
although the site (macrophage (MQ) and/or parasite) and
mechanism of reduction (enzymatic or nonezymatic) are unde-
fined. The second checkpoint involves a regulatory mechanism
promoting reduced influx and/or enhanced efflux/sequestration
of active drug that lowers its intracellular accumulation [2,3].
Importantly, these two events are largely dependent on the
intracellular level of thiol compounds such as glutathione
(cglutamylcysteinylglycine, GSH) and parasite-specific trypa-
nothione, which in turn are regulated by both host- and LD-
cglutamylcysteine synthetase, a rate-limiting enzyme in glutathi-
one biosynthesis [2–5]. Although the increased expression of
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strains of LD is controversial [3–6], inhibition of cGCS by
buthionine sulfoxamine (BSO) reverses Sb
III resistance in LD [7].
Therefore, cGCS expression contributes to antimony resistance in
LD by regulating intracellular thiol level.
In addition to the mechanisms noted above, the unresponsive-
ness of kala-azar patients to treatment with SAG is also believed to
be a consequence of skewed type-2 immune response that
suppresses interferon (IFN) c-mediated protective immunity [8].
Nonetheless, IFNc production by T cells is reduced in non-
responders compared to SAG-responders [8,9]. The endogenous
production of IFNc and importantly, its principal inducer IL-12,
determine the anti-leishmanial efficacy of SAG in a fully
immunocompetent host infected with LD [10,11]. Following LD
infection, the early production of IL-12 is exclusively mediated by
dendritic cells (DCs) [12]. This tempted us to speculate a possible
involvement of DCs in regulating ‘‘SAG responsiveness’’ versus
‘‘unresponsiveness’’ in kala-azar patients.
DCs normally play a key role in initiating and regulating
Leishmania-specific T cell reactivity [13,14]. However, the T cell
stimulatory capacity of DCs depends on their state of activation
and maturation. In contrast to mature DCs, immature DCs
exhibit a reduced capacity to stimulate T cells due to low
expression of MHC and co-stimulatory molecules, and the lack of
production of proinflammatory cytokines. Gene expression
associated with the development, activation, maturation and
antigen-presenting cell (APC) function of DCs is largely regulated
by the transcription factor NF-kB [15–18]. For instance, inhibition
of NF-kB activation suppresses DC maturation and APC function
[19,20]. NF-kB is a hetero- or homo-dimeric complex of
structurally related proteins p50, p52, p65 (RelA), cRel and RelB.
In resting cells, NF-kB is sequestered in the cytoplasm by the
inhibitory proteins IkBa,I kBb and IkBe [21]. However, cellular
activation with wide range of stimuli such as LPS, TNFa and IL-
1phosphorylates and thereby activates a multisubunit complex IkB
kinase (IKK) consisting of IKKa/IKK1, IKKb/IKK2 and
IKKc/NEMO [22]. Subsequently, activated IKK promotes
downstream events, for example, phosphorylation followed by
polyubiquitination and 26S proteasome-mediated degradation of
IkB proteins [21]. NF-kB dimers then translocate to the nucleus,
and bind to consensus sequences to induce gene transcription.
Notably, the phosphatidylinositol 3-kinase (PI3K)/AKT pathway
has been demonstrated in a variety of models to regulate NF-kB
activation [20,23,24].
Studies demonstrated that stimulation with SAG induces the
PI3K/AKT pathway and enhances production of proinflamma-
tory cytokines and leishmanicidal effector molecules in MQ [25].
Furthermore, SAG stimulates NF-kB activation in different cell
types, such as CD4
+ T cells and peripheral blood mononuclear
cells [26]. Importantly, blockade of NF-kB activation is shown to
impair cGCS expression in murine MQ-like cell line [27].
However, direct role of NF-kB in transcriptional regulation of
murine cGCS promoter is undefined. With this in mind, the
current study was initiated to define the role of SAG in murine DC
activation and its regulation by LD isolates with SAG-resistant
(Sb
RLD) and SAG-sensitive (Sb
SLD) phenotype. We demonstrate
that Sb
RLD but not Sb
SLD infection suppresses SAG-induced
activation/maturation and cGCS expression of DCs by inhibiting
NF-kB activation in a PI3K/AKT-dependent manner.
Results
Sb
SLD- and Sb
RLD-infected DCs respond differentially to
SAG treatment
Although MQs are regarded as a ‘‘primary target’’ for
leishmanial infection, recent studies indicate DC infection with
various Leishmania spp. including LD [28,29]. Indeed, LD infection
was observed in both immature bone marrow-derived DC
(BMDC) (CD11c
+CD8a
-) and splenic DC (sDC) (Figure 1A). To
determine the leishmanicidal effect of SAG on intracellular
Sb
RLD and Sb
SLD in DCs, BMDCs and sDCs were infected
with GFP expressing promastigotes of Sb
SLD strain 2001 (GFP-
2001) or Sb
RLD strain R5 (GFP-R5) for 3 hours, stimulated with
SAG (20 mg/ml) for 24 hours, and the frequency of infected DCs
measured via flow cytometry. A comparable level of DC infection
was observed with both GFP-2001 and GFP-R5 (Figure 1B).
However, the percentage of BMDCs or sDCs infected with GFP-
2001 (Sb
SLD) was reduced by 5 to 9-fold following SAG treatment
(Figure 1B). In marked contrast, SAG treatment failed to exhibit
any significant effect on GFP-R5 (Sb
RLD) infection in DCs
(Figure 1B). Furthermore, analyses via Giemsa staining demon-
strated that intracellular amastigotes of other Sb
RLD strains
exhibit similar resistance to the SAG-induced leishmanicidal effect
in DCs. For instance, a significant reduction in both percentage of
infected BMDCs and intracellular parasite number were observed
in AG83 (Sb
SLD)- and to a lesser extent in 39 (Sb
RLD)-infected
BMDCs after SAG treatment (10 and 20 mg/ml) for 24 and 48
hours (Figure S1). Titration of parasites demonstrated that parasite
to DC ratio (multiplicity of infection; MOI) of 10:1 was the
optimum ratio for maximum LD infection in DCs (data not
shown). Therefore, this MOI was used for all subsequent
experiments unless otherwise stated.
Next, the regulation of SAG-induced activation and maturation
of DCs by Sb
RLD and Sb
SLD was investigated. For this purpose,
BMDCs and sDCs were infected with Sb
RLD and Sb
SLD
promastigotes for 3 hours, washed and cultured with or without
SAG (20 mg/ml) for an additional 48 hours. The activation and
maturation of DCs were determined by analyzing MHC and co-
stimulatory molecule expression and secretion of cytokines.
Author Summary
Kala-azar, a life-threatening parasitic disease caused by
Leishmania donovani (LD), is widening its base in different
parts of the world. Currently, there is no effective vaccine
against kala-azar. The antimonial drugs like sodium
antimony gluconate (SAG) have been the mainstay of
therapy for this disease. Recently, due to the emergence of
antimony-resistance in parasites, SAG often fails to cure
kala-azar patients, which is compounding the disaster
further. It is still unknown how infection with LD exhibiting
antimony-resistant phenotype, in contrast to antimony-
sensitive phenotype, is handled by the kala-azar patients
upon SAG treatment. This demands an understanding of
the nature of host immune responses against these two
distinct categories of parasites. Accordingly, we compared
the impact of infection with LD exhibiting antimony-
resistant versus antimony-sensitive phenotype on dendrit-
ic cells (DCs). DCs upon activation/maturation initiate anti-
leishmanial immunity. We showed that parasites with
antimony-resistant but not antimony-sensitive phenotype
prevented SAG-induced DC activation/maturation by
blocking activation of NF-kB. The latter is a key signaling
pathway regulating DC activation/maturation. Our studies
for the first time provide both a cellular and molecular
basis for differential response of host cells to parasite
isolates with antimony-resistant and antimony-sensitive
phenotype, which may influence the outcome of the
disease.
Antimony-Resistant L. donovani Inhibits DC
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RLD- and Sb
SLD-infected DCs. (A) BMDCs and ex vivo derived sDCs were infected
with 2001 promastigotes (Sb
SLD) in vitro at a MOI of 10:1 for overnight, washed thoroughly to remove free parasites and localization of intracellular
LD parasites was ascertained via Giemsa staining. (B) BMDCs and sDCs were infected in vitro with GFP-2001 (Sb
SLD) or GFP-R5 (Sb
RLD) promastigotes,
as described above, for 3 hours or left uninfected. Free parasites were removed from DCs by thorough washing. The LD-infected DCs were then
cultured with or without SAG treatment (20 mg/ml) for another 24 hours whereas uninfected DCs were left untreated. DCs were immunostained with
aCD11c-PE and LD infection in DC was analyzed by FACS. Numbers in upper right quadrant indicate the percentage of LD-infected DCs as
represented by CD11c
+GFP
+ cells. In some experiments (C-F), BMDCs were infected with Sb
SLD (AG83, 2001) or Sb
RLD (39, GE1F8R) strains for 3 hours
or left uninfected as described above. DCs were then washed to remove free parasites and stimulated with SAG (20 mg/ml) for 48 hours and (C) IL-10,
(D) IL-12p70 and (E) TNFa secretion in culture supernatants were measured via ELISA or (F) surface expression of co-stimulatory molecules and MHCs
measured via FACS. Open histograms represent untreated DCs and shaded histograms represent DCs plus SAG. For this and all other figures the label
‘‘Uninf’’ represents uninfected DCs. Data are the representative of three independent experiments.
*p,0.001 versus DC+AG83;
"p=0.001,
#p=0.002
and
**p=0.003 versus DC+2001;
{p,0.001,
{{p=0.004 and
1p=0.002 versus DC+SAG (Student’s t test). Error bars indicate mean 6 SD.
doi:10.1371/journal.ppat.1000907.g001
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RLD strains 39 or GE1F8R
induced more IL-10 production as compared with Sb
SLD strains
AG83 or 2001 (Figures 1C and S2A). Interestingly, IL-10 secretion
from Sb
RLD-infected DCs was not affected by SAG treatment
(Figures 1C and S2A). In contrast, SAG treatment significantly
inhibited IL-10 secretion by Sb
SLD-infected DCs (Figures 1C and
S2A). Furthermore, SAG-stimulated secretion of proinflammatory
cytokines such as IL-12p70 and TNFa from DCs were inhibited
by Sb
RLD and not Sb
SLD infection (Figures 1D-E and S2B-C).
Finally, SAG treatment up-regulated CD40, CD80, CD86, MHC-
I (H2K
d) and MHC-II (IA
d) expression in BMDCs infected with
Sb
SLD but not Sb
RLD (Figure 1F). Consistent with work by other
groups [30,31], co-stimulatory molecule and MHC expression of
untreated BMDCs remained unaltered following Sb
RLD or
Sb
SLD infection (Figure 1F). Together, these results demonstrate
that SAG treatment protects DCs from Sb
SLD but not Sb
RLD
infection. Moreover, stimulation with SAG fails to activate and
mature Sb
RLD-infected DCs, while Sb
SLD-infected DCs are still
capable of activation and maturation upon SAG treatment.
SAG treatment induces NF-kB activation in DCs
Since NF-kB is a key regulator of maturation and APC function
of DCs, the effect of SAG treatment on NF-kB activation was
investigated. BMDCs were treated with SAG for varying times
and DNA binding activity of nuclear NF-kB was determined via
electrophoretic mobility shift assay (EMSA). Relative to untreated
BMDCs, a 23-fold increase in NF-kB DNA binding activity was
initially observed by 0.3 hours, which persisted up to 1 hour after
SAG treatment (Figure 2A). Notably, OCT-1 DNA binding was
unaltered despite SAG treatment indicating that SAG-induced
enhancement of nuclear DNA binding was NF-kB-specific
(Figure 2A). Furthermore, supershift analysis using antibodies
specific for each Rel family member demonstrated that SAG
stimulation of BMDCs induced DNA binding of NF-kB complexes
consisting of the p50, p65 and RelB subunits (Figure 2B). In
contrast to SAG, BMDC treatment with varying concentrations
(25 to 200 mg/ml) of sodium gluconate for 0.3 hours, or 200 mg/
ml of sodium gluconate for various times failed to induce DNA
binding activity of NF-kB (Figure 2C-D).
Consistent with the EMSA data, SAG treatment for 0.3, 0.5 and
1 hour induced degradation of IkB proteins in BMDCs
(Figure 3A). Importantly, SAG-induced IkB degradation corre-
sponded to enhanced IkBa phosphorylation (Figure 3B), which
could be due to increased activity of upstream IKK complex. To
test this hypothesis, BMDCs were stimulated with SAG for 0.3, 0.5
and 1 hour. IKK signalosome was immunoprecipitated from
cytoplasmic extracts and kinase activity of the complex determined
by measuring phosphorylation of an IkBa-GST substrate in vitro.
BMDCs stimulated with SAG for 0.3, 0.5 and 1 hour exhibited
approximately 3.6 to 4.7-fold increase in IKK activity compared
Figure 2. Stimulation with SAG increases nuclear NF-kB DNA binding activity in BMDCs. BMDCs were treated with SAG (20 mg/ml) or
specified concentrations of sodium gluconate (SG) for indicated times or left untreated. (A, C-D) DNA binding activity of nuclear NF-kB to H2K-specific
oligonucleotide probe was measured via EMSA. The OCT-1 DNA binding was used as an internal control. Densitometric analysis represents the ratio
of intensity of NF-kB to OCT-1 binding per unit area and is represented as arbitrary units. (B) Binding of different NF-kB complexes to H2K-DNA probe
was determined by supershift EMSA using rabbit IgG (Control Ab) or Abs specific for different NF-kB subunits. For this and all other figures, control
(Cont) lane represents uninfected DCs without SAG stimulation. Data are representative of three independent experiments. Error bars indicate mean
6 SD.
doi:10.1371/journal.ppat.1000907.g002
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IKK1 and IKK2 proteins were similar in all BMDC extracts
(Figure 3C). The SAG-induced NF-kB DNA binding, IkBa
degradation and IKK activity were also observed in sDCs (Figure
S3).
Of note, SAG treatment failed to activate the mitogen-
activated protein kinase (MAPK) pathway in BMDCs. In contrast
to LPS stimulation, phosphorylation of p38MAPK, ERK1/
ERK2 and JNK was not detected in SAG-treated DCs
(Figure 3D-F). Collectively, these findings demonstrate that
stimulation with SAG induces activation of the IKK complex,
phosphorylation and degradation of IkB proteins and down-
stream nuclear DNA binding of NF-kB in both BMDCs and
sDCs, and that the induction of these events in DC is contributed
by antimonial moiety of SAG. Furthermore, among different
signaling pathways, which are known to regulate DC activation/
maturation, NF-kB signaling is selectively induced by SAG
treatment.
Figure 3. SAG-treated BMDCs exhibit increased phosphorylation and degradation of IkB proteins and IKK activity. BMDCs were
untreated or stimulated either with 20 mg/ml SAG (A-F) or 500 ng/ml LPS (D-F) for specified times. (A) Expression of IkBa,I kBb,I kBe and b-actin
protein in cytoplasmic extracts was detected by Western blot using the same blot. Densitometric analyses represent the ratio of intensity of the
corresponding IkB protein to b-actin expression per unit area and are represented as an arbitrary unit. (B) Cytoplasmic phospho-IkBa versus b-actin
protein expression was detected via Western blot with the same blot. (C) In vitro IKK activity was determined by measuring phosphorylation of an
IkBa-GST substrate. IKK1 and IKK2 protein expression in immunoprecipitated samples was analyzed via Western blot. Densitometric analysis indicates
the intensity of phosphorylated (P) IkBa-GST substrate in an arbitrary unit. The levels of (D) phospho-p38MAPK versus p38MAPK, (E) phospho-ERK
versus ERK and (F) phospho-JNK versus JNK protein expression in whole cell lysates were determined via Western blot. Data are representative of
three independent experiments. Error bars indicate mean 6 SD.
doi:10.1371/journal.ppat.1000907.g003
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RLD but not Sb
SLD infection inhibits SAG-induced NF-
kB activation in DCs
The effect(s) of Sb
RLD and Sb
SLD infection on SAG-stimulated
NF-kB activation in DCs was determined. BMDCs were infected
with either promastigotes or amastigotes of 39 (Sb
RLD) or 2001
(Sb
SLD) for varying times, stimulated with SAG for 0.3 hours and
nuclear NF-kB DNA binding activity to H2K-specific probe
measured via EMSA. SAG-induced NF-kB activity was complete-
ly inhibited in BMDCs upon infection with either 39 promasti-
gotes (39Pm) or amastigotes (39Am) (Sb
RLD) at all times of LD
infection analyzed (Figure 4A-B). In contrast, BMDC infection
with 2001 promastigotes (2001Pm) or amastigotes (2001Am)
(Sb
SLD) for up to 6 and 3 hours, respectively, failed to inhibit
SAG-stimulated NF-kB DNA binding (Figure 4A-B). SAG-
induced NF-kB DNA binding activity was also inhibited in
39Pm (Sb
RLD)-infected sDCs (Figure S4A). The ability of Sb
RLD
to block SAG-stimulated NF-kB DNA binding in DCs was not LD
strain specific. For example, BMDC infection with promastigotes
of Sb
RLD strain GE1F8R (GE1F8RPm), unlike Sb
SLD strain
AG83 (AG83Pm), completely prevented SAG-induced NF-kB
DNA binding (Figure S4B).
Our finding that SAG-induced NF-kB activity is inhibited
selectively in Sb
RLD-infected BMDCs was further confirmed by
temporal analysis of IkB protein degradation and activation of
IKK. BMDC infection with either 2001Pm or 2001Am (Sb
SLD)
for up to 6 or 3 hours, respectively, had no significant effect on
SAG-induced IkB degradation (Figure 4C-D). In contrast, IkB
degradation stimulated by SAG was persistently inhibited by 39
(Sb
RLD) regardless of the duration of BMDC infection and form
of parasite (Figure 4C-D). SAG-induced IkBa degradation was
similarly inhibited in sDCs infected with 39Pm (Sb
RLD) and
BMDCs infected with promastigotes of a different Sb
RLD strain
(Figure S4C-D). Interestingly, inhibition of SAG-induced IkB
degradation corresponded with a reduction in IkBa phosphory-
lation in BMDCs infected with Sb
RLD promastigotes (Figure 4C,
E). Furthermore, SAG-induced IKK activation as determined by
in vitro IKK activity or phosphorylation of IKK1 and IKK2 was
inhibited in extracts prepared from BMDCs and sDCs infected
with Sb
RLD but not Sb
SLD promastigotes (Figures 4F and S4E-F).
BMDC infection with Sb
RLD and not Sb
SLD amastigotes also
blocked SAG-stimulated IKK activity (Figure 4G). Additionally,
pretreatment of BMDCs with parasite antigen(s) (Sb
RLDsAg) or
culture supernatant (Sb
RLDs) of Sb
RLD inhibited SAG-induced
NF-kB DNA binding activity, IkB degradation and IKK activity;
whereas culture supernatant of Sb
SLD (Sb
SLDs) or Sb
SLD-
derived antigen(s) (Sb
SLDsAg) did not (Figure 5).
As demonstrated in Figure 4A-D; SAG-induced NF-kB
activation was inhibited in BMDCs infected at a MOI 10:1
(promastigote or amastigote to DC) with Sb
SLD promastigotes or
amastigotes for 24 or 6 hours, respectively, similar to Sb
RLD-
infected BMDCs. Accordingly, we tested whether the increased
intracellular parasite number at these time points of infection
rendered 20 mg/ml of SAG insufficient to activate NF-kB. In fact,
number of intracellular 2001 (Sb
SLD) or 39 (Sb
RLD) was
significantly increased if BMDCs were infected with promastigotes
for 24 hours rather than 6 hours (Figure S5A). Likewise, BMDCs
infected with amastigotes of the above LD strains for 6 hours
exhibited increased intracellular parasite number compared to
BMDCs infected for 3 hours (Figure S5B). Notably, SAG (20 mg/
ml)-induced NF-kB DNA binding and IkBa degradation were
detected despite the presence of intracellular parasites in BMDCs
infected with 2001Pm and 2001Am (Sb
SLD) for 6 and 3 hours,
respectively (Figures 4A-D and S5A-B). Therefore, these two time
points of BMDC infection were selected as a ‘‘reference’’ to
analyze the basis of defective SAG-induced NF-kB activation in
BMDCs infected with 2001Pm or 2001Am (Sb
SLD) for 24 or 6
hours, respectively. Initially, the association of increased intracel-
lular parasite number with impairment of SAG-induced NF-kB
activation was verified in both BMDCs infected with 2001Pm or
2001Am (Sb
SLD) for 24 or 6 hours, respectively. For this purpose,
BMDCs were infected with 2001Pm (Sb
SLD) or 39Pm (Sb
RLD)
for 24 hours at varying MOIs and stimulated with SAG (20 mg/
ml) for 0.3 hours. Despite LD infection for fixed duration (24
hours), this approach established varying levels of intracellular
parasite number, which was elevated in BMDCs infected at MOI
10:1 compared to other MOIs (Figure S6A). BMDC infection with
both 2001Pm (Sb
SLD) and 39Pm (Sb
RLD) at a MOI 10:1
inhibited SAG-induced NF-kB DNA binding activity and IkBa
degradation (Figure 6A-B). However, SAG-induced NF-kB DNA
binding activity and IkBa degradation were observed only in
2001Pm (Sb
SLD)-infected BMDCs but not 39Pm (Sb
RLD)-
infected BMDCs when BMDC infection was done at MOIs
2.5:1 and 5:1 (Figure 6A-B). Notably, at each of these MOIs both
2001Pm (Sb
SLD)-infected BMDCs and 39Pm (Sb
RLD)-infected
BMDCs had comparable level of intracellular parasite number
(Figure S6A). Using identical MOIs for BMDC infection, similar
results were obtained when the intracellular parasite number and
SAG-induced NF-kB activation were analyzed in BMDCs infected
for 6 hours with 39Am (Sb
RLD) and 2001Am (Sb
SLD)
(Figures 6C-D and S6B). These findings suggest that irrespective
of the form of parasite, 2001 (Sb
SLD) and 39 (Sb
RLD)
differentially regulate SAG-induced NF-kB signaling in DCs with
low intracellular parasite number.
It is possible that with increased intracellular parasite number
2001(Sb
SLD), similar to 39 (Sb
RLD), developed the capacity to
inhibit SAG-induced NF-kB activation and that occurred when
BMDCs were infected at a MOI 10:1 with 2001Pm or 2001Am
(Sb
SLD) for 24 and 6 hours, respectively. However, this possibility
was ruled out when NF-kB activation in response to 20 and
40 mg/ml of SAG treatment was analyzed in BMDCs infected for
6 and 24 hours with 2001Pm (Sb
SLD) or 39Pm (Sb
RLD) at a MOI
of 10:1. The effect of SAG (40 mg/ml) stimulation was also verified
in BMDCs infected similarly with 2001Am or 39Am for 3 and 6
hours. Stimulation with both 20 and 40 mg/ml of SAG induced
NF-kB DNA binding and IkBa degradation in BMDCs infected
with 2001Pm (Sb
SLD) for 6 hours (Figure 6E-F). In contrast,
BMDCs infected for 24 hours with 2001Pm (Sb
SLD) exhibited
enhanced NF-kB DNA binding and IkBa degradation only when
stimulated with 40 mg/ml of SAG (Figure 6E-F). Similarly, the
inhibition of SAG-induced NF-kB DNA binding and IkBa
degradation due to BMDC infection with 2001Am (Sb
SLD) for
6 hours was overcome by increasing the dose of SAG from 20 to
40 mg/ml (Figure 6G-H). On the contrary, 39Pm/39Am (Sb
RLD)
continued to suppress NF-kB DNA binding and IkBa degradation
at various durations of infection tested irrespective of dose of SAG
used for stimulation (Figure 6E-H). Together, these results
demonstrate that SAG-induced NF-kB signaling is impaired by
Sb
RLD infection of DCs.
Sb
RLD inhibits SAG-induced NF-kB signaling, DC
activation and leishmanicidal effects by suppressing the
PI3K/AKT pathway in an IL-10-independent manner
Stimulation with SAG induces PI3K/AKT activation in MQ
[25]. Furthermore, PI3K/AKT regulates the NF-kB pathway in
DCs via IKK [19,20]. Therefore, the possibility that SAG-induced
activation of NF-kB in DCs is PI3K/AKT-dependent was
investigated. Initially, the effect of SAG stimulation on AKT
activation was assessed by measuring phosphorylation of AKT.
Antimony-Resistant L. donovani Inhibits DC
PLoS Pathogens | www.plospathogens.org 6 May 2010 | Volume 6 | Issue 5 | e1000907Figure 4. SAG-induced NF-kB signaling is inhibited in Sb
RLD- and not Sb
SLD-infected DCs. BMDCs were infected in vitro with
promastigotes (Pm) (A, C, E-F) or amastigotes (Am) (B, D, G) of specified strains of Sb
SLD or Sb
RLD at a MOI 10:1 for indicated times or left uninfected.
DCs were then stimulated with SAG (20 mg/ml) for 0.3 hours. (A-B) Nuclear DNA binding of NF-kB to H2K-specific probe was measured via EMSA. DNA
binding of OCT-1 was used as internal control. Densitometric analyses were determined by measuring the ratio of intensity of NF-kB to OCT-1 binding
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to 7-fold increase in AKT phosphorylation in BMDCs (Figure 7A).
Notably, SAG-induced AKT phosphorylation was not observed in
BMDCs pretreated with PI3K inhibitors wortmannin (Wort) or
Ly294002 (Ly) (Figure 7A). Next, the effect of PI3K inhibitors on
SAG-induced NF-kB signaling was determined. Pretreatment with
Wort or Ly effectively blocked SAG-induced IKK activity, IkBa
degradation and nuclear NF-kB DNA binding in BMDCs
(Figure 7B-D). Importantly, infection of BMDCs and sDCs with
39Pm (Sb
RLD) but not 2001Pm (Sb
SLD) for 3 hours inhibited
SAG (20 mg/ml)-induced AKT phosphorylation (Figures 7E and
S7). SAG (20 mg/ml)-induced AKT phosphorylation was also
inhibited due to BMDCs infection for 1 and 3 hours with 39Am
(Sb
RLD) but not 2001Am (Sb
SLD) (Figure 7F). Similar to 39Pm
(Sb
RLD)-infected BMDCs, SAG (20 mg/ml)-induced AKT phos-
phorylation, however, was not observed if BMDCs were infected
with 2001Pm (Sb
SLD) for 24 hours (Figure 7G). Interestingly,
AKT phosphorylation was observed in these 2001Pm (Sb
SLD)-
infected BMDCs but not 39Pm (Sb
RLD)-infected BMDCs upon
stimulation with of 40 mg/ml of SAG (Figure 7G).
Since Sb
RLD infection stimulated high IL-10 secretion by DCs
(Figures 1C and S2A), the possibility that Sb
RLD inhibited SAG-
induced PI3K/AKT (Figures 7E-F and S7) and NF-kB pathways
(Figures 4 and S4) in an IL-10-dependent manner was investigated
by using a neutralizing aIL-10 Ab. Temporal analyses demon-
strated that significant IL-10 production by BMDCs was initially
detected after an infection for 12 hours with Sb
RLD but not
Sb
SLD promastigotes (Figure 7H). Compared to Sb
SLD-infected
BMDCs, IL-10 production was significantly increased in BMDCs
infected with Sb
RLD for 24 and 48 hours (Figure 7H). Strikingly,
SAG-induced AKT phosphorylation and NF-kB DNA binding
activity were not restored in BMDCs infected with Sb
RLD for 3
and 24 hours despite aIL-10 Ab treatment (Figure 7I-J). However,
aIL-10 Ab treatment effectively prevented inhibition of LPS-
induced NF-kB DNA binding in BMDCs pretreated with IL-10
(Figure S8). Therefore, this finding ruled out the involvement of
IL-10 in suppression of SAG-induced PI3K/AKT and NF-kB
pathways in Sb
RLD-infected BMDCs.
Consistent with previous report [5], an overexpression of ATP-
binding cassette (ABC) transporter MRPA (PGPA) was observed in
Sb
RLD strains 39Pm and GE1F8RPm (Figure S9A). Whether
MRPA plays any role in mediating the inhibitory effects of Sb
RLD
on SAG-induced PI3K/AKT and NF-kB activation in DC was
then investigated. Accordingly, SAG-induced AKT phosphoryla-
tion and NF-kB activation in BMDCs infected for 3 hours with
39Pm (Sb
RLD), 2001Pm (Sb
SLD) and isogenic 2001Pm expressing
MRPA (2001Pm-MRPA) (Figure S9B) were compared. The latter
was developed by transfecting 2001Pm (Sb
SLD) with a DNA
construct expressing MRPA. A complete blockade of SAG-induced
AKT phosphorylation and NF-kB DNA binding activity was
observed in 39Pm (Sb
RLD)-infected BMDCs (Figure 8A-B). In
contrast, SAG-induced AKT phosphorylation and NF-kB DNA
bindingactivityweredetectedin2001Pm(Sb
SLD)-infectedBMDCs
(Figure 8A-B). However, infection of BMDCs with 2001Pm-MRPA
inhibited SAG-induced AKT phosphorylation and DNA binding
activity of NF-kB in BMDCs, albeit partially (Figure 8A-B).
Next, a direct role for PI3K in Sb
RLD and Sb
SLD regulation of
SAG-induced proinflammatory cytokine secretion and leishmani-
cidal effects in DCs was investigated using Wort or Ly. In contrast
to 39Pm (Sb
RLD)-infected BMDCs, SAG-stimulated IL-12 and
TNFa production were observed in both uninfected and 2001Pm
(Sb
SLD)-infected BMDCs (Figure 9A-B). However, pretreatment
of uninfected and 2001Pm (Sb
SLD)-infected BMDCs with Wort or
Ly significantly inhibited SAG-induced secretion of IL-12 and
TNFa (Figure 9A-B). Furthermore, PI3K inhibitors prevented
SAG (20 mg/ml)-induced reduction of percentage of infected
BMDCs and intracellular parasite number in BMDCs infected for
3 hours with 2001Pm (Sb
SLD) (Figure 9C-D). Importantly,
BMDCs infected with 2001Pm (Sb
SLD) for 24 hours exhibited a
significant reduction in both percentage of infected BMDCs and
intracellular parasite number only when treated with 40 but not
20 mg/ml of SAG (Figure S10). Treatment of these 2001Pm
(Sb
SLD)-infected BMDCs with Wort or Ly blocked the leishma-
nicidal effects of SAG (40 mg/ml) (Figure S10). In contrast to
2001Pm (Sb
SLD)-infected BMDCs, SAG-induced leishmanicidal
effects were not observed in 39Pm (Sb
RLD)-infected BMDCs
regardless of duration of infection and dose of SAG (Figures 9C-D
and S10). In addition, BMDC infection for 3 hours with 2001Pm-
MRPA, unlike 2001Pm (Sb
SLD), partly but significantly sup-
pressed SAG-induced leishmanicidal effects (Figure 9E-F). Collec-
tively, these data demonstrate that blockade of PI3K/AKT
pathway by Sb
RLD impairs SAG-induced NF-kB signaling, DC
activation and leishmanicidal function and that is IL-10-indepen-
dent. Furthermore, these inhibitory effects of Sb
RLD are partly
contributed by MRPA.
Inhibition of NF-kB activation by Sb
RLD suppresses SAG-
stimulated murine cGCS heavy-chain gene expression in
DC
Previous studies have demonstrated an association of antimony
resistance of leishmanial parasite with cGCS heavy-chain
(cGCShc) gene expression of host [4]. The latter encodes the
catalytic subunit of cGCS [32]. In fact, a comparative analysis
demonstrated that SAG-induced murine cGCShc (mcGCShc)
expression was unaffected in 2001Pm (Sb
SLD)-infected BMDCs
but selectively inhibited in 39Pm (Sb
RLD)-infected BMDCs
(Figure 10A). The molecular basis for Sb
RLD-mediated suppres-
sion of mcGCShc expression in DC was then explored. Despite
SAG stimulation, the inhibition of mcGCShc expression could be
due to suppression of NF-kB activation in Sb
RLD-infected
BMDC. To investigate this possibility, the regulatory role of NF-
kBi nm cGCShc promoter activity was initially ascertained. An
approximately 1.0 kb DNA sequence upstream of the transcrip-
tional start site of mcGCShc gene (Mus musculus chromosome 9
genomic contig, NT_039474.7; GI:149260095) was selected as the
promoter region using Ensembl and UCSC browsers. The
mcGCShc promoter was found to contain a putative NF-kB
binding site
-904GGGGAAACTT
-895 that differs from the
consensus sequence GGGRNNYYCC at positions 7, 9 and 10
(Figure 10B). ChIP analysis demonstrated that SAG treatment of
BMDCs induced NF-kB binding to 2991/2673 region of
mcGCShc promoter that includes the sequence
-904GGGGA-
AACTT
-895 (Figure 10B-C). Furthermore, DNA binding of NF-kB
complexes consisting of p50, RelB and p65 subunits specifically to
the sequence
-904GGGGAAACTT
-895 in SAG-treated BMDCs
was confirmed via EMSA using mcGCShc probes containing wild-
type sequence
-904GGGGAAACTT
-895 (WT-mcGCShc probe) or
per unit area and represented as arbitrary units. (C-D) Cytoplasmic IkBa,I kBb,I kBe and b-actin protein were detected via Western blot with same blot.
(E) Phospho-IkBa was detected by Western blot. The same blot was reprobed for b-actin. (F-G) In vitro IKK activity and expression of IKK1 and IKK2
were determined as in Figure 3. Data are representative of three independent experiments. Error bars indicate mean 6 SD.
doi:10.1371/journal.ppat.1000907.g004
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-904CTCTAAGAAT
-895 (Mut-mcGCShc probe)
(Figure 10D) and supershift analysis (Figure 10E).
Next, the role of NF-kB binding site
-904GGGGAAACTT
-895 in
regulation of promoter activity of mcGCShc gene was tested via
luciferase reporter assay using p987-luc and Mut p987-luc, the
reporter constructs of mcGCShc promoter fragment containing
wild-type and mutant NF-kB binding site, respectively. Compared
to control vector (pEGFP-C1) transfected cells, expression of NF-
kB subunit p65 strongly induced luciferase activity of p987-luc
(Figure 10F). This enhanced luciferase activity of p987-luc was
completely blocked upon co-transfection with pEGFP-dominant
negative IkBa (pEGFP-IkBaDN) encoding the NF-kB-specific
inhibitor, IkBaDN (Figure 10F). The lack of luciferase activity of
Mut p987-luc despite p65 expression (Figure 10F) further
Figure 5. DC pretreatment with antigens or culture supernatant of Sb
RLD inhibits SAG-induced NF-kB pathway. BMDCs were either
pretreated with antigens prepared from indicated strains of Sb
SLD (Sb
SLDsAg) or Sb
RLD (Sb
RLDsAg) (A-C) or cultured in RPMI 1640 complete medium
containing culture supernatants of indicated strains of Sb
SLD (Sb
SLDs) or Sb
RLD (Sb
RLDs) at a complete medium to supernatant ratios of 1:1 (D) or 1:3
(D-F) for 3 hours. BMDCs were then washed and stimulated with SAG (20 mg/ml) for 0.3 hours. (A, D-E) Nuclear NF-kB binding to H2K-DNA probe or
OCT-1 DNA binding was measured via EMSA. (B, F) Cytoplasmic IkBa,I kBb,I kBe and b-actin expression were detected by Western blot using the
same blot. (C) In vitro IKK activity was determined as in Figure 3 and the same blot was reprobed for IKK1 and IKK2 protein. Data are representative of
three independent experiments.
doi:10.1371/journal.ppat.1000907.g005
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-904GGGGAAACTT
-895 is required
for NF-kB-mediated transcriptional activation of mcGCShc gene.
Interestingly, SAG-induced NF-kB DNA binding to WT-
mcGCShc probe was inhibited in 39Pm (Sb
RLD)-infected BMDCs
(Figure 10G). In contrast, SAG-induced NF-kB DNA binding to
WT-mcGCShc probe was readily detected in 2001Pm (Sb
SLD)-
infected BMDCs (Figure 10G). These findings suggest that Sb
RLD
suppresses SAG-induced mcGCShc expression in DC by inhibiting
NF-kB DNA binding to the mcGCShc promoter.
Discussion
Antimonial drugs activate innate effector cells to promote an
anti-leishmanial effect [25]. However, regulation of antimonial
Figure 6. SAG-induced NF-kB activation is restored in Sb
SLD- but not Sb
RLD-infected DCs despite prolonged infection. BMDCs were
infected with promastigotes of 2001 (2001Pm) (Sb
SLD) and 39 (39Pm) (Sb
RLD) (A-B, E-F); or amastigotes of 2001 (2001Am) (Sb
SLD) and 39 (39Am)
(Sb
RLD) (C-D, G-H) for indicated times at MOIs as specified (A-D) or 10:1 (E-H). BMDCs were then stimulated with specified concentrations of SAG for
0.3 hours. (A, C, E, G) Nuclear NF-kB binding to H2K-DNA probe or OCT-1 DNA binding was measured via EMSA. (B, D, F, H) Cytoplasmic IkBa and b-
actin expression were detected by Western blot using the same blot. SAG20 and SAG40 represent stimulation of BMDCs with 20 and 40 mg/ml of SAG,
respectively. Data are representative of three independent experiments.
doi:10.1371/journal.ppat.1000907.g006
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RLD inhibits SAG-induced NF-kB signaling in an IL-10 independent manner. BMDCs were infected
with promastigotes of Sb
SLD strains 2001(2001Pm) (E, G-J) and AG83 (AG83Pm) (H), and Sb
RLD strains 39 (39Pm) (E, G-J) and GE1F8R (GE1F8Pm) (H); or
amastigotes of 2001(2001Am)and39 (39Am) (F) for indicated times or left uninfected as described in Figure 4. Subsequently, BMDCs were stimulated or
not with 20 (A-J) or 40 (G) mg/ml of SAG for specified times. For experiments (A-D), uninfected BMDCs were treated with 200 nM Wort or 50 mM Ly for 1
hour prior to SAG stimulation. In some experiments (I-J), BMDCs infected with 2001Pm (Sb
SLD) or 39Pm (Sb
RLD) for 3 or 24 hours were treated with
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RLD and Sb
SLD is ill-
defined. This is of particular interest in view of the lack of efficacy
of antimonial compounds reported for SAG-unresponsive kala-
azar patients. Recent studies indicated that DCs play a key role in
regulating anti-leishmanial immune response [12–14,33]. Accord-
ingly, the role of SAG in activation of DCs, its regulation by
Sb
RLD and Sb
SLD and the molecular mechanism involved
therein were investigated. Here we provide evidence that Sb
RLD
and Sb
SLD differentially regulate activation of DCs. Furthermore,
SAG-induced signaling pathway associated with DC activation is
selectively targeted by Sb
RLD infection.
In an agreement with an earlier report [28], both BMDCs and
ex vivo sDCs were infected in vitro with LD promastigotes
(Figure 1A). The ‘‘SAG-resistant’’ phenotype did not significantly
affect the efficiency of LD infection, but did impact the
susceptibility of LD to the leishmanicidal effects of SAG. In
contrast, SAG treatment significantly impaired DC infectivity of
Sb
SLD including reduction in both intracellular parasite number
and percentage of infected DCs (Figures 1B and S1). The
differential response of Sb
RLD and Sb
SLD towards SAG
treatment was also noted in their ability to regulate activation
and maturation of DCs. In contrast to Sb
SLD, Sb
RLD infection
10 mg/ml of neutralizing aIL-10 mAb or isotype control Ab as described in Materials and Methods section or left untreated, and stimulated with SAG. (A,
E-G, I) AKT phosphorylation in cytoplasmic extract was determined via Western blot and the same blot was reprobed for AKT protein. (B) In vitro IKK
activity was measured as in Figure 3. IKK1 and IKK2 protein expression were determined via Western blot using the same blot. (C) Cytoplasmic IkBa and
b-actin were detected by Western blot with the same blot. (D, J) Nuclear DNA binding activity of NF-kB to H2K-DNA probe or OCT-1 DNA binding was
determined via EMSA. (H) Secretion of IL-10 was measured via ELISA. SAG20 and SAG40 represent stimulation of BMDCs with 20 and 40 mg/ml of SAG,
respectively. Data are representative of three independent experiments.
*p,0.005 versus DC;
{p,0.005,
{p=0.006 and
1p=0.007 versus DC+AG83Pm;
#p,0.005 versus DC+2001Pm of respective times (Student’s t test). Error bars indicate mean 6 SD.
doi:10.1371/journal.ppat.1000907.g007
Figure 8. 2001Pm-MRPA but not 2001Pm inhibits SAG-induced AKT phosphorylation and DNA binding activity of NF-kB. BMDCs
were infected for 3 hours with 2001Pm (Sb
SLD), 39Pm (Sb
RLD), 2001Pm expressing MRPA (2001Pm-MRPA) or 2001Pm transfected with empty vector
(2001Pm-EV) and stimulated with 20 mg/ml of SAG as described in Figure 4. (A) Expression of phosphorylated (P) AKT and AKT were measured in
whole cell lysates via Western blot using the same membrane. Densitometric readings represent the ratio of intensity of phosphorylated (P) AKT
protein to AKT expression per unit area and are represented as arbitrary units. (B) Nuclear NF-kB and OCT-1 DNA binding activities were measured via
EMSA. Densitometric analysis represents the ratio of intensity of NF-kB to OCT-1 binding per unit area and is represented as arbitrary units. Data are
representative of two independent experiments. Error bars indicate mean 6 SD.
doi:10.1371/journal.ppat.1000907.g008
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up-regulation of co-stimulatory molecule and MHC expression in
DCs (Figures 1D-F and S2B-C). Noteworthy is that Sb
RLD
induced increased IL-10 secretion by DCs compared to Sb
SLD
(Figures 1C and S2A). This finding reinforces the inherent ability
of Sb
RLD and Sb
SLD to differentially immunoregulate DC
activation. Previous studies demonstrated that IL-10, a potent
suppressor of anti-leishmanial immunity, minimizes responsiveness
to SAG [34,35]. Therefore, increased IL-10 production may play
a critical role in disease pathogenesis in the host infected with
Sb
RLD.
The second important finding arising from this study is that
both promastigotes and amastigotes of Sb
RLD and Sb
SLD
differentially regulate SAG-induced NF-kB activation in DCs.
Indeed, Sb
RLD but not Sb
SLD infection blocks SAG-induced NF-
kB signaling by suppressing IKK activation, and IkB protein
phosphorylation and degradation (Figures 4 and S4). In this
regard, it should be noted that SAG stimulation of uninfected DCs
induced concomitant degradation of all three IkB proteins
(Figure 3A), although degradation of IkBe generally occurs with
delayed kinetics upon cellular activation [36,37]. This finding,
however, is consistent with a number of studies reporting rapid
degradation of IkBb and IkBe depending on the type of cell and
the nature of the stimulation [19,20,36–39]. Nevertheless, the
suppression of SAG-induced IkB protein degradation by Sb
RLD
ultimately impaired nuclear NF-kB DNA binding activity
(Figures 4 and S4). Surprisingly, BMDC infection at a MOI
10:1 with Sb
SLD promastigotes or amastigotes for 24 or 6 hours,
respectively, also inhibited SAG (20 mg/ml)-induced NF-kB
activation (Figure 4). SAG (20 mg/ml)-induced NF-kB activation
was restored in these BMDCs but not Sb
RLD-infected BMDCs
upon lowering the MOIs (,10:1) for BMDC infection, which
established reduced levels of intracellular parasite number
compared to MOI 10:1(Figures 6A-D and S6). This finding
suggests that intracellular parasite number plays a critical role for
differential regulation of SAG-induced NF-kB activation by
Sb
RLD and Sb
SLD. The early inhibition of NF-kB activation in
Sb
SLD amastigote versus promastigote-infected BMDCs (Figure 4)
is in agreement with the fact that DCs internalize amastigotes
more efficiently than promastigotes [40–42]. However, Sb
RLD
and Sb
SLD still retain their ability to differentially regulate SAG-
induced NF-kB activation in BMDCs with high intracellular
parasite number. This conclusion is supported by results
demonstrating that despite stimulation with 40 mg/ml of SAG,
NF-kB activation was blocked in BMDCs infected for above
durations with Sb
RLD amastigotes or promastigotes at a MOI
10:1 but readily observed in BMDCs infected similarly with
Sb
SLD (Figure 6). Here, the SAG dose was increased from 20 to
40 mg/ml keeping in mind that SAG therapy requires multiple
dosing schedules to ensure enough antimony accumulation in
tissues of kala-azar patients [43]. Furthermore, equivalent and/or
increased concentrations of SAG have previously been used by
other groups [44,45]. Under identical conditions, the recurrence of
NF-kB activation in Sb
SLD-infected BMDCs by increasing the
dose of SAG from 20 to 40 mg/ml (Figure 6) further suggested that
20 mg/ml of SAG was insufficient to activate NF-kB in these
BMDCs due to high intracellular parasite number.
Noteworthy is that the inhibitory effect on NF-kB activation was
not dependent on live Sb
RLD. For instance, parasite antigens
derived from Sb
RLD (Sb
RLDsAg) and Sb
RLD culture supernatant
(Sb
RLDs) but not the Sb
SLD-derived antigens (Sb
SLDsAg) or
culture supernatant of Sb
SLD (Sb
SLDs) efficiently inhibited SAG-
induced NF-kB activation (Figure 5). These findings suggest that
the inhibition of NF-kB activation is specific for Sb
RLD/Sb
RLD-
derived antigen(s)/factor(s) secreted by Sb
RLD. Strikingly, the
inhibition of NF-kB activation correlated with suppression of
SAG-induced DC activation by Sb
RLD infection (Figures 1, 4 and
S2). Studies involving gene transfer of a modified IkBa
recombinant into immature DC demonstrated that blockade of
NF-kB activation alone prevents up-regulation of co-stimulatory
molecule expression and production of proinflammatory cytokines
[16,18]. Based on these reports coupled with our own observa-
tions, we conclude that the Sb
RLD blocks SAG-induced NF-kB
signaling to prevent DC activation and maturation.
Our results further suggest that Sb
RLD inhibits IKK and NF-
kB activation by blocking SAG-induced PI3K/AKT signaling.
SAG stimulation of DCs induced PI3K activation as measured by
phosphorylation of AKT, a downstream signaling mediator of
PI3K (Figures 7A and S7). Blockade of PI3K/AKT activation by
Wort or Ly completely suppressed SAG-stimulated IKK activity
and NF-kB signaling (Figure 7A-D), indicating a direct involve-
ment of the PI3K/AKT pathway in NF-kB activation by SAG in
DCs. Importantly, PI3K/AKT activation is negatively regulated
by Src homology phosphotyrosine phosphatase (SHP)-1, which
dephosphorylates PI3K [46]. Furthermore, SHP-1activity is
inhibited by SAG [47]. Therefore, blockade of SHP-1activity by
SAG may indirectly promote PI3K phosphorylation and activa-
tion of downstream AKT, IKK and NF-kB in DCs. Similar to
uninfected DCs, SAG treatment induced PI3K/AKT activation in
DCs infected with Sb
SLD promastigotes for 3 hours and Sb
SLD
amastigotes for 1 and 3 hours (Figures 7E-F and S7). Importantly,
PI3K inhibitors impaired SAG (20 mg/ml)-induced NF-kB
pathway, DC activation and leishmanicidal effects in BMDCs
infected with Sb
SLD promastigotes for 3 hours (Figures 9 and
S11). These results suggest the inability of Sb
SLD to regulate SAG-
induced PI3K/AKT and NF-kB pathways. Consequently, SAG
continues to exhibit leishmanicidal effects in Sb
SLD-infected DCs.
The inability of Sb
SLD to regulate SAG-induced leishmanicidal
effects was maintained despite BMDC infection for 24 hours with
Sb
SLD promastigotes. This was apparent when increased dose of
SAG (40 mg/ml) was used for treatment (Figure S10). In fact,
treatment with 40 mg/ml of SAG restored AKT phosphorylation
and therefore exhibited leishmanicidal effects in a PI3K-
dependent manner in these Sb
SLD-infected BMDCs (Figures 7G
and S10). Interestingly, Sb
RLD infection mimicked the effects of
the PI3K inhibitors in that all SAG-induced events as mentioned
above were also blocked by Sb
RLD regardless of duration of
infection, form of parasite and dose of SAG (Figures 7, 9, S10 and
S11). One intriguing possibility is that IL-10 produced by Sb
RLD-
infected DCs mediated Sb
RLD-induced suppression of PI3K/
Figure 9. Sb
RLD inhibits SAG-induced proinflammatory cytokine production and leishmanicidal effects by suppressing PI3K/AKT
pathway. BMDCs were infected for 3 hours with Sb
RLD strain 39Pm (A-F); Sb
SLD strain 2001Pm (A-F); 2001Pm expressing MRPA (2001Pm-MRPA) (E-
F); or 2001Pm transfected with empty vector (2001Pm-EV) (E-F) or left uninfected as described in Figure 4. BMDCs were washed and then stimulated
with SAG (20 mg/ml) for 48 (A-B) or 24 (C-F) hours. For experiments (A-D); uninfected BMDCs (A-B), and BMDCs infected with 2001Pm (Sb
SLD) (A-D) or
39Pm (Sb
RLD) (C-D) were treated with 200 nM Wort or 50 mM Ly for 1 hour prior to SAG treatment. (A-B) Secretion of IL-12 (A) and TNFa (B) were
determined by ELISA. (C-F) Giemsa staining was performed to determine the percentage of infected BMDCs (C, E) and number of intracellular
amastigotes per 1000 BMDCs (D, F). Data are representative of three independent experiments.
*p,0.001 and
{p,0.005 versus DC+SAG;
**p,0.001
and
{{p,0.005 versus DC+2001Pm+SAG;
#p,0.04 versus DC+2001Pm (Sb
SLD) or DC+2001Pm-EV (Student’s t test). Error bars indicate mean 6 SD.
doi:10.1371/journal.ppat.1000907.g009
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RLD is NF-kB-dependent. Both uninfected BMDCs (A, C-E, G) and
BMDCs infected with 2001Pm (Sb
SLD) or 39Pm (Sb
RLD) for 3 hours (A, G) were stimulated with SAG (20 mg/ml) for specified times as in Figure 4. (A)
The mRNA expression of mcGCShc versus mGAPDH was determined via RT-PCR. Densitometric data represent ratio of intensity of mcGCShc to
mGAPDH mRNA expression per unit area and are presented as an arbitrary unit. (B) Schematic presentation of mcGCShc promoter indicating the
position of NF-kB binding site and ChIP primers (P1, P2). (C) NF-kB binding to 2991/2673 region of mcGCShc promoter was examined by ChIP using
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correlation can be made because IL-10 inhibits AKT activation
and NF-kB pathway in DCs [19]. Furthermore, the inhibitory
effects of IL-10 on DCs can be mediated in an autocrine manner
[48]. However, this is unlikely since SAG-induced NF-kB
activation was inhibited even in BMDCs infected with Sb
RLD
for 1 and 3 hours, when IL-10 production was not detected
(Figures 4 and 7H). Moreover, neutralization of IL-10 produced
by BMDCs upon Sb
RLD infection for 24 hours failed to block
Sb
RLD-induced inhibition of PI3K/AKT and NF-kB pathways
(Figure 7H-J). Therefore, Sb
RLD infection of BMDCs for up to 24
hours inhibits SAG-induced PI3K/AKT and NF-kB pathways in
an IL-10-independent manner and eventually impairs DC
activation.
Another key finding is that the suppression of NF-kB activation
by Sb
RLD but not Sb
SLD inhibits not only DC activation but also
SAG-induced mcGCShc expression in DC (Figure 10). Impor-
tantly, regulation of host cGCShc expression and therefore host
GSH level by Sb
RLD plays a key role for antimony resistance in
LD infection [4]. Although regulation of cGCShc expression by
NF-kB was shown in a murine MQ-like cell line by blocking NF-
kB activation [27], our observation establishes a direct role for NF-
kB in mediating the promoter activity of the mcGCShc gene
(Figure 10C-F). Interestingly, Sb
RLD blocked SAG-induced
mcGCShc expression in DC by preventing NF-kB binding to
the mcGCShc gene promoter (Figure 10G). This suggests a key
role for NF-kBi nS b
RLD-mediated suppression of mcGCShc
expression in DC. Our findings (Figures 10A and S12) are
consistent with the recent work by Carter and colleagues
demonstrating that Sb
RLD transcriptionally down-regulate host
cGCShc expression and up-regulate their own cGCShc (LD-
cGCShc) expression [4]. Whereas Sb
RLD-induced inhibition of
host cGCS expression reduces host GSH level and impairs
reduction of Sb
V to toxic Sb
III form; elevated expression of LD
cGCS by Sb
RLD restores GSH level that promotes efflux of SAG
and confers protection against oxidative stress [4].
The mechanism of antimony resistance in clinical LD isolates is
unknown and may differ from laboratory-derived resistant
parasites [3]. The true markers of clinical antimony resistance in
LD isolates are still lacking [2]. A gene, PG1, is reported to confer
antimony resistance in clinical isolates of LD [45,49]. In addition,
enhanced expression of several other genes including MRPA and
proteophosphoglycans (PPG) was demonstrated in antimony-
resistant compared to antimony-sensitive field isolates (Salotra P,
Singh R, Nakhasi H. 2005. Clinical Microbiology and Infection.
Vol 11, Suppl 2: 47) [5,50]. As an initial effort to determine
whether any Sb
RLD-specific factor(s) mediated the suppression of
SAG-induced NF-kB signaling and leishmanicidal effects in DCs,
the role for MRPA was investigated. Results obtained using
2001Pm and its isogenic strain expressing MRPA (2001Pm-
MRPA) showed that the inhibitory effect of 2001Pm-MRPA on
SAG-induced PI3K/AKT and NF-kB pathways and leishmani-
cidal activities mimics that of Sb
RLD to some extent (Figures 8 and
9). However, the real bearing of this observation in naturally
occurring antimony-resistant LD isolates is still questionable and
needs detailed investigation further. Moreover, the effects of SAG
are likely to be inhibited in DCs by other Sb
RLD-specific factor(s)
also. The relative contribution of these parasite-specific factors in
Sb
RLD-mediated suppression of DC activation is currently under
investigation. Furthermore, an association of antimony resistance
with genetic variation among LD strains has been proposed [51].
Recent studies demonstrated that due to high genetic polymor-
phism, strain 39 is remarkably distinct not only from antimony-
sensitive strain 2001 but also from other antimony-resistant clinical
LD isolates exhibiting homology with antimony-sensitive parasites
[51]. On the other hand, the antimony-sensitive strains 2001 and
Dd8 exhibit significant genetic similarity [51]. The extreme
genetic polymorphism might be a potential cause of antimony
resistance in strain 39 [51]. These reports together with our
findings emphasize the notion that antimony resistance of clinical
LD isolates is ‘‘multifactorial’’ [3].
SAG unresponsiveness in kala-azar patients also entails a
number of host-regulated events including dominance of a type-
2 T cell response and altered host gene expression [3,4,8,9]. Our
findings demonstrate that SAG treatment induces PI3K-depen-
dent NF-kB activation in DCs, which is blocked by Sb
RLD but not
Sb
SLD infection. Dysregulation of SAG-induced NF-kB activation
favors persistent survival of Sb
RLD in DCs despite SAG treatment
by: 1) inhibiting NF-kB-dependent mcGCS expression, a key
mediator of Sb
V reduction to Sb
III, and 2) preventing DC
activation and maturation required for the initiation of the anti-
leishmanial immune response. Notably, a heterogeneous response
to SAG treatment may be observed in humans. This possibility is
raised by a report demonstrating that SAG treatment of
monocyte-derived DCs restores their capacity to respond to LPS
in ,60% of type 1diabetes patients [52]. Importantly, some
variability in SAG responsiveness is also reported in kala-azar
patients [53]. It is speculated that the genetic differences among
individuals may influence the response following SAG therapy in
the patients infected with same Leishmania species and living in the
same endemic area [54]. Further studies are needed to define how
genetic variation, if any, influences the outcome of SAG treatment
in kala-azar patients.
Materials and Methods
Animals
BALB/c mice and golden hamsters (Mesocricetus auratus) were
maintained and bred under pathogen-free conditions.
Ethics statement
Use of both mice and hamsters was approved by the
Institutional Animal Ethics Committees of Institute of Microbial
Technology and Indian Institute of Chemical Biology, India. All
the primers shown in B and indicated Abs. Amplification of mGAPDH promoter and chromatin immunoprecipitated by rabbit IgG were used as
negative controls, and input DNA (2%) as an internal control. (D, G) Nuclear NF-kB DNA binding to mcGCShc promoter-specific probes containing
wild-type NF-kB binding site (WT-mcGCShc probe) (D, G) or mutant NF-kB binding site (Mut-mcGCShc probe) (D) was determined via EMSA. OCT-1
DNA binding activity was used as internal control. (E) DNA binding of different NF-kB complexes to WT-mcGCShc probe was determined via supershift
analysis using rabbit IgG (Control Ab) or Abs specific for indicated NF-kB subunits. (F) NF-kB-mediated regulation of mcGCShc promoter activity was
determined by reporter assay. NIH3T3 cells were co-transfected with Renilla luciferase vector (pRL-CMV) and firefly luciferase reporter plasmid
containing mcGCShc promoter with wild-type (p987-luc) or mutant (Mut p987-luc) NF-kB binding site. In addition, all co-transfections contained
pEGFP-C1 empty vector or pEGFP-p65 and/or pEGFP-IkBaDN. Twenty-four hours later, firefly and Renilla luciferase activities in cell lysates were
measured. The data represent the fold induction of firefly/Renilla luciferase activity ratio relative to pEGFP-C1-transfected cells. Data are
representative of three independent experiments.
*p,0.001 versus NIH3T3+p987-luc+pEGFP-C1 and
{p,0.001 versus NIH3T3+p987-luc+pEGFP-p65
(Student’s t test). Error bars indicate mean 6 SD.
doi:10.1371/journal.ppat.1000907.g010
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National Regulatory Guidelines issued by CPSEA (Committee
for the Purpose of Supervision of Experiments on Animals),
Ministry of Environment and Forest, Govt. of India.
Parasite cultures and preparation of soluble antigen from
LD
Sb
RLD [GE1F8R (MHOM/IN/89/GE1), 39, R5] and Sb
SLD
[AG83 (MHOM/IN/83/AG83), 2001] strains are gifts from Dr.
Neeloo Singh (Central Drug Research Institute, India) and Dr.
Shyam Sundar (Banaras Hindu University, India) and were
maintained in golden hamsters as described [45,55–57]. Amasti-
gotes were obtained from spleens of infected hamsters as described
[58]. Subsequently, amastigotes were transformed into promasti-
gotes and maintained as described [59]. GFP-2001 and GFP-R5
are gifts from Dr. Neeloo Singh and were maintained in M199
complete medium (10% FBS, penicillin/streptomycin) with
720 mg/ml geneticin disulfate (G418) (Sigma, St. Louis, MO)
[60]. Soluble antigens were prepared from Sb
SLD and Sb
RLD
promastigotes (10
9/ml) as described [59].
Transfection of 2001Pm
2001Pm (Sb
SLD) at mid log or stationary phase were washed
twice with electroporation buffer (21 mM HEPES, pH 7.05;
137 mM NaCl; 5 mM KCl; 0.7 mM NaH2PO4; 6 mM glucose).
The promastigotes were resuspended in ice-cold electroporation
buffer to a final concentration of 10
7/ml. An aliquot (400 ml) of
parasite suspension was mixed with 35–40 mg of chilled pGEM
7ZF a-neo-a L. tarentolae MRPA or pGEM 7ZF a-neo-a DNA
(kind gifts from Dr. Marc Ouellette, Laval University, Canada),
transferred to a 2-mm gap cuvette and electroporated using BIO-
RAD Gene-Pulser X cell instrument at 450 V and 500 mF (3.5 to 4
milli-seconds pulse time). After electroporation, parasites were
immediately placed on ice for 10 minutes and cultured at 22uC for
24 hours in Schneider’s insect medium with 1500 mg/ml
paromomycin and 10 mM Biopterin. Subsequently, 40 mg/ml of
G418 was added to the parasite culture. After 24 hours, 1 ml of
this promastigote culture was transferred to a new flask containing
5 ml of fresh medium with 10 mM biopterin and 120 mg/ml G418.
The culture was maintained for one month under drug pressure
(once per week) to obtain the stable transfectants. The mRNA
expression of MRPA in these stable transfectants was verified via
RT-PCR.
DC preparation
BMDCs and sDCs were prepared from male or female BALB/c
mice between 8–12 weeks of age as described [19]. Flow
cytometric analyses indicated .85% and ,90% purity of BMDCs
and sDCs, respectively, based on CD11c expression.
DC infection with promastigotes or amastigotes of LD
DCs (5610
6/well) were infected in vitro at specified MOIs either
with amastigotes of Sb
RLD or Sb
SLD; or promastigotes of
stationary phase Sb
RLD, Sb
SLD or respective GFP-LD for
indicated times in a 6-well plate in RPMI 1640 complete medium
(10% FBS, penicillin/streptomycin, L-glutamine, sodium pyru-
vate, non-essential amino acids, 2-mercaptoethanol). Subsequent-
ly, DCs were washed, resuspended in RPMI 1640 complete
medium and stimulated with SAG (10, 20 and 40 mg/ml) of
clinical grade or sodium gluconate (25, 50, 100 and 200 mg/ml) for
specified times. The doses of SAG mentioned here and for all
experiments represent the concentration of Sb
V. DC infection with
GFP-Sb
RLD or GFP-Sb
SLD was determined via flow cytometry.
SAG containing 20 mg/ml of Sb
V, and 35 mg/ml of sodium
gluconate had equivalent molar concentration. Sodium gluconate
was purchased from Acros Organics, New Jersey, USA. SAG was
obtained as kind gift from Albert David Ltd., Kolkata, India. For
other experiments, DCs (2.5610
5/ml) were adhered on
22622 mm cover slips, infected with promastigotes/amastigotes
of Sb
SLD or Sb
RLD and treated with SAG for indicated times.
The number of intracellular parasites in DCs was determined via
Giemsa staining. In some experiments, DCs (5610
6/well) were
infected with Sb
SLD or Sb
RLD promastigotes for 3 hours or left
uninfected. Alternatively, infection of DCs (5610
6/well) with LD
promastigotes was done for specified times. DCs were then treated
or not with Wort (200 nM) or Ly (50 mM) (Cell Signaling
Technology, Beverly, MA) 1 hour prior to SAG stimulation as
described [19]. In some cases, DCs (5610
6/well) were infected
with Sb
SLD or Sb
RLD promastigotes for 3 and 24 hours or left
uninfected. Neutralizing aIL-10 monoclonal Ab (10 mg/ml)/
isotype control rat IgG2b Ab (10 mg/ml) (BD Biosciences, San
Jose, CA) were added at 2
nd hour of BMDC infection. After
infection, DCs were washed and stimulated with SAG for 0.3
hours.
DC pretreatment with soluble antigens/culture
supernatant of LD or IL-10
DCs (5610
6/well) were pretreated for 3 hours with 50 mg/ml
soluble antigens derived from Sb
RLD (Sb
RLDsAg) or Sb
SLD
(Sb
SLDsAg) and stimulated with SAG for 0.3 hours in a 6-well
plate. Alternatively, Sb
RLD or Sb
SLD promastigotes (10
6/ml)
were grown in M199 complete medium till the parasite
concentration reached $10
7/ml. The respective culture superna-
tants of Sb
RLD (Sb
RLDs) and Sb
SLD (Sb
SLDs) were then
collected. Subsequently, DCs (5610
6/well) were cultured for 3
hours in RPMI 1640 complete medium containing Sb
RLDs or
Sb
SLDs at specified complete medium to supernatant ratios and
stimulated with SAG for 0.3 hours as above. In some experiments,
BMDCs (5610
6/well) were pretreated with murine IL-10 (50 ng/
ml) (PeproTech, Rocky Hill, NJ) for 24 hours as described [19], in
the presence or absence of 10 mg/ml of aIL-10Ab/isotype control
Ab and stimulated with LPS (500 ng/ml) for 0.5 hours.
EMSA and Western blot
Nuclear and cytoplasmic extracts were prepared from DC as
described [61]. EMSA was performed as described [62] using
32P-
labeled DNA probes containing NF-kB binding sites derived from
MHC-I H2K promoter:
59-CAGGGCTGGGGATTCCCCATCTCCACAGTTT-
CACTTC-39 [20]. In some experiments, DNA probes specific for
murine cGCS heavy-chain (mcGCShc) promoter containing wild-
type or mutant NF-kB binding sites as represented by WT-
mcGCShc probe, 9-CGGTTCTGAAGGTGGGGAAACTTCT-
GAAGAAACTT-395and Mut-mcGCShc probe, 59-CGGTT-
CTGAAGGTCTCTAAGAATCTGAAGAAACTT-39 (NF-kB bi-
nding site is underlined and mutated bases are in italics)
respectively, were used. A double stranded OCT-1 DNA probe,
59-TGTCGAATGCAAATCACTAGAA-39 was used as control.
Supershift EMSAs were carried out as described [19] using
following Abs: ap50, aRelB (Active Motif, CA); ap65 (Abcam plc.
Cambridge, UK); ap52, acRel, rabbit IgG (Santa Cruz Biotech-
nology, Santa Cruz, CA). Bands were visualized using a
phosphoimager (Bio-Rad Molecular Imager FX, Hercules, CA).
Western blotting was carried out as described [20]. Blots were
probed with Abs specific for: IkBa,I kBb,I kBe, IKK1, IKK2
(Santa Cruz Biotechnology); pIkBa, pIKK1 (Ser180)/pIKK2
(Ser181), pAKT (Ser473), AKT, pSAPK/JNK (Thr183/Tyr185),
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pERK1/pERK2 (Thr202/Tyr204), ERK1/ERK2 (Cell Signaling
Technology); b-actin (Sigma). Binding of secondary HRP-labeled
goat-arabbit (Santa Cruz Biotechnology) or goat-amouse Abs
(Sigma) was analyzed using SuperSignal
R West Pico or West Dura
Chemiluminescent Substrate (Pierce, Rockland, IL).
IKK assay
IKK signalosome was immunoprecipitated from 700 mgo fa
whole DC lysate using Protein A/G agarose beads (Santa Cruz
Biotechnology) and rabbit polyclonal aIKK1 Ab. In vitro kinase
reaction was performed and kinase activity of immunoprecipitated
IKK complex determined as described [20].
Flow cytometry
The following monoclonal antibodies used for flow cytometry
were purchased from eBioscience (San Diego, CA): PE-amouse
CD11c, FITC-amouse CD11b, FITC-amouse CD40, FITC-
amouse CD86, FITC-amouse CD80, FITC-amouse H2K
d and
FITC-amouse IA
d. The fluorescence of stained cells was analyzed
on a FACSCalibur (BD Biosciences) using Cell Quest Pro
software.
Measurement of IL-12, TNFa and IL-10 secretions from
DCs
DCs (1610
6/ml) were infected with promastigotes of Sb
RLD or
Sb
SLD for 3 hours or left uninfected, washed and stimulated with
SAG for additional 48 hours in a 24-well plate. Alternatively, DCs
(1610
6/ml) were infected with promastigotes of Sb
RLD or Sb
SLD
for varying times or left uninfected. The culture supernatants were
analyzed for IL-12, TNFa and IL-10 productions in triplicate
using ELISA kits (BD Biosciences) following the manufacturer’s
instructions.
Analysis of murine cGCS heavy-chain (mcGCShc) and LD
cGCS heavy-chain (LD-cGCShc) expression in Sb
RLD- and
Sb
SLD-infected BMDCs
BMDCs (5610
6/well) were infected with Sb
RLD or Sb
SLD for
3 hours or left uninfected, stimulated with SAG for 3 hours and
RNA prepared using RNeasy minikit reagent (QIAGEN). The
mRNA expression of mcGCShc, LD-cGCShc, murine glyceralde-
hyde-3-phosphate dehydrogenase (mGAPDH) and LD-tubulin
genes were determined via reverse transcription-PCR using
platinum quantitative RT-PCR Thermoscript One Step system
kit (Invitrogen, Carlsbad, CA), and primers: LD-cGCShc 59-
TATCAAGTCTCGCTACGACT-39,5 9-CGGAGTCCTTCA-
GAAGTT-39; LD-tubulin 59-ACATCACGAACTCGGTGTTT-
39,5 9-TTCGTCTTGATCGTCGCAAT-39;m cGCShc 59-
AGAACAATCGCTTTAGGATCA-39,5 9-AGAAGATGATC-
GATGCCTTC-39; mGAPDH 59-AGATTGTTGCCATCAAC-
GAC 39,5 9-ATGACAAGCTTCCCATTCTC-39 [4].
Detection of MRPA expression in LD
RNA was isolated from LD promastigotes and mRNA
expression of MRPA was detected by analyzing the amplification
of 179 bp cDNA fragment of MRPA via reverse transcription-
PCR using primers: 59-GCGCAGCCGTTTGTGCTTGTGG-
39,5 9-TTGCCGTACGTCGCGATGGTGC-39 [5]. mRNA ex-
pression of LD-tubulin was used as loading control.
Chromatin immunoprecipitation (ChIP)
BMDCs (5610
6/well) were stimulated with SAG for 0.3 hours
or left untreated. ChIP was performed using ChIP-IT kit (Active
Motif) following the manufacturer’s instructions. After immuno-
precipitation using rabbit IgG or NF-kB Abs such as ap50, aRelB
and ap65, followed by DNA extraction; PCR was performed to
amplify 2991/2673 region of mcGCShc promoter using primers:
P1, 59-CCAGTTCCCAGAGCCTTCCG-39 and P2, 59-TT-
GTACGACTCCACATGGCATG-39. For a negative control,
mGAPDH promoter was amplified by using primers: 59-
CACCCTGGCATTTTCTTCCA-3 and 59-GACCCAGA-
GACCTGAATGCTG-39 [63].
Reporter assay
An approximately 1.0 kb (2987/+25) long 59-flanking sequence
of mcGCShc gene was amplified by PCR using murine genomic
DNA (Promega, Madison, WI) and cloned into pGL3-Basic
vector. Using this resulting construct, p987-luc, and a Quick-
ChangeII PCR-based site-directed mutagenesis kit (Stratagene,
Cedar Creek, TX); the construct (Mut p987-luc) containing a
mutant NF-kB binding site, similar to that described in EMSA
studies, in 2987/+25 region of mcGCShc promoter was
generated. Both constructs were confirmed by sequencing.
NIH3T3 cells were transiently transfected with a DNA mixture
containing p987-luc or Mut p987-luc (0.266 mg), pRL-CMV
(0.200 mg), pEGFP-p65 (0.266 mg) and/or pEGFP-IkBaDN( I kBa
with amino acids 1–36 deleted) (0.266 mg) using lipofectamine
LTX (Invitrogen). The latter two expression vectors are gifts from
Dr. Johannes Schmid (Medical University of Vienna, Austria) and
Dr. Susan Kandarian (Boston University, USA) respectively
[64,65]. The DNA amount in each transfection was kept constant.
Cells were grown for 24 hours after transfection. The luciferase
activity of the cell lysates was determined using Dual Luciferase
Reporter Assay System (Promega) and GLOMAX luminometer
(Promega) following the manufacturer’s instructions. The level of
luciferase activity was normalized to the level of Renilla luciferase
activity.
Supporting Information
Figure S1 BMDC infection with AG83Pm but not 39Pm is
inhibited by SAG treatment. BMDCs were infected in vitro at MOI
10:1 with AG83Pm (Sb
SLD) or 39Pm (Sb
RLD) for 3 hours and
stimulated with SAG (10 and 20 mg/ml) for 24 and 48 hours as
described in Figure 1. Untreated (24h) and untreated (48h)
represent LD-infected DC controls cultured without SAG
treatment for 24 and 48 hours, respectively. The percentage of
infected BMDCs (A) and number of intracellular amastigotes per
1000 BMDCs (B) were determined by Giemsa staining. Open and
solid bars represent AG83Pm and 39Pm-infected BMDCs,
respectively. Data are representative of three independent
experiments.
*p,0.001,
**p=0.003,
{p=0.002 and
{{p=0.0012
versus DC+AG83Pm of respective times (Student’s t test). Error
bars indicate mean 6 SD.
Found at: doi:10.1371/journal.ppat.1000907.s001 (1.94 MB TIF)
Figure S2 Sb
SLD and Sb
RLD differentially regulate cytokine
secretion by sDCs. Ex vivo derived sDCs were infected with
2001Pm (Sb
SLD) or 39Pm (Sb
RLD) for 3 hours or left uninfected.
sDCs were then washed to remove free parasites and stimulated
with SAG (20 mg/ml) for 48 hours as in Figure 1. Production of (A)
IL-10, (B) IL-12p70 and (C) TNFa in the culture supernatants
were measured via ELISA. Data are representative of three
independent experiments.
*p=0.004 and
**p=0.008 versus
DC+2001;
{p,0.001 versus DC+SAG (Student’s t test). Error
bars indicate mean 6 SD.
Found at: doi:10.1371/journal.ppat.1000907.s002 (1.63 MB TIF)
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sDCs were stimulated with SAG (20 mg/ml) for the specified times
or left untreated. (A) EMSA was used to measure DNA binding
activity of nuclear NF-kB to H2K-DNA probe. OCT-1 DNA
binding was used as internal control. (B) Western blot was used to
detect cytoplasmic IkBa and b-actin protein using the same blot.
(C) In vitro IKK activity was determined as described in Figure 3.
Expression of IKK1 and IKK2 were determined via Western blot
using same membrane. Data are representative of three indepen-
dent experiments.
Found at: doi:10.1371/journal.ppat.1000907.s003 (0.94 MB TIF)
Figure S4 BMDCs and sDCs infection with Sb
RLD strains
GE1F8R and 39, respectively, inhibits SAG-induced NF-kB
signaling. sDCs were infected with 2001Pm (Sb
SLD) or 39Pm
(Sb
RLD) (A, C, E) and BMDCs with AG83Pm (Sb
SLD) or
GE1F8RPm (Sb
RLD) (B, D, F) for 3 hours as described in Figure 4.
DCs were then washed and stimulated with SAG (20 mg/ml) for
0.3 hours. (A-B) Nuclear NF-kB or OCT-1 DNA binding activity
was determined via EMSA. (C-D) Cytoplasmic IkBa and b-actin
protein were detected by Western blot using the same blot. (E)
IKK phosphorylation was detected via Western blot and the same
blot was reprobed for IKK1 and IKK2 protein. (F) In vitro IKK
activity, and IKK1 and IKK2 protein expression were determined
as described in Figure 3. Data are representative of three
independent experiments.
Found at: doi:10.1371/journal.ppat.1000907.s004 (3.51 MB TIF)
Figure S5 Temporal analysis of DC infection with Sb
RLD and
Sb
SLD. BMDCs were infected at a MOI 10:1 with promastigotes
(Pm) (A, C) or amastigotes (Am) (B, D) of indicated Sb
RLD and
Sb
SLD strains for specified times. BMDCs were subsequently
washed to remove free parasites. The number of intracellular
amastigotes per 1000 BMDCs (A-B) and percentage of infected
BMDCs (C-D) were determined by Giemsa staining. Data are
representative of three independent experiments.
*p,0.01 versus
BMDCs infected with 2001Pm for 6 hours,
#p,0.01 versus
BMDCs infected with 39Pm for 6 hours,
{p= 0.014 versus
BMDCs infected with 2001Am for 3 hours and
{{p=0.011 versus
BMDCs infected with 39Am for 3 hours (Student’s t test). Error
bars indicate mean 6 SD.
Found at: doi:10.1371/journal.ppat.1000907.s005 (3.38 MB TIF)
Figure S6 DC infection varies with MOIs at specified time
points of infection. BMDCs were infected at varying MOIs either
with 2001Pm (Sb
SLD) or 39Pm (Sb
RLD) for 24 hours (A, C); or
2001Am (Sb
SLD) or 39Am (Sb
RLD) for 6 hours (B, D). BMDCs
were then washed. The number of intracellular amastigotes per
1000 BMDCs (A-B) and percentage of infected BMDCs (C-D)
were determined by Giemsa staining. Data are representative of
three independent experiments.
*p,0.005 versus BMDCs infected
with 2001Pm at MOIs 2.5:1 or 5:1 (promastigote:BMDC);
#p,0.01 and
##p,0.005 versus BMDCs infected with 39Pm at
MOIs 2.5:1 or 5:1 (promastigote:BMDC);
"p,0.005 versus
BMDCs infected with 2001Am at MOIs 2.5:1 or 5:1 (amastigo-
te:BMDC);
**p,0.005 and
{p,0.01 versus BMDCs infected with
39Am at MOIs 2.5:1 or 5:1 (amastigote:BMDC) (Student’s t test).
Error bars indicate mean 6 SD.
Found at: doi:10.1371/journal.ppat.1000907.s006 (3.34 MB TIF)
Figure S7 Sb
RLD but not Sb
SLD infection inhibits SAG-
stimulated phosphorylation of AKT in sDCs. Ex vivo sDCs were
infected with 2001Pm (Sb
SLD) or 39Pm (Sb
RLD) for 3 hours at a
MOI 10:1 or left uninfected. The sDCs were washed thoroughly
and stimulated with SAG (20 mg/ml) for 0.3 hours. Expression of
phospho-AKT versus AKT in the cytoplasmic extract was
determined via Western blot. Data are representative of two
independent experiments.
Found at: doi:10.1371/journal.ppat.1000907.s007 (0.51 MB TIF)
Figure S8 Treatment with aIL-10 Ab prevents inhibition of
LPS-induced NF-kB DNA binding activity in IL-10-pretreated
BMDCs. BMDCs were pretreated with IL-10 (50 ng/ml) for 24
hours in the presence or absence of 10 mg/ml of aIL-10 Ab or
isotype control Ab. BMDCs were then washed and stimulated with
LPS (500 ng/ml) for 0.5 hours. Nuclear NF-kB binding to H2K-
DNA probe or OCT-1 DNA binding was measured via EMSA.
Data are representative of two independent experiments.
Found at: doi:10.1371/journal.ppat.1000907.s008 (0.62 MB TIF)
Figure S9 An increased expression of MRPA is detected in
Sb
RLD and 2001Pm-MRPA but not Sb
SLD. The mRNA
expression of MRPA versus LD-tubulin in Sb
RLD strains 39Pm
and GE1F8RPm (A); Sb
SLD strains AG83Pm (A) and 2001Pm (A-
B); 2001Pm expressing MRPA (2001Pm-MRPA) (B); and 2001Pm
transfected with empty vector (2001Pm-EV) (B) was determined
via RT-PCR. Densitometric data represent ratio of intensity of
MRPA to LD-tubulin mRNA expression per unit area and are
presented as an arbitrary unit. Data are representative of three
independent experiments. Error bars indicate mean 6 SD.
Found at: doi:10.1371/journal.ppat.1000907.s009 (2.76 MB TIF)
Figure S10 SAG (40 mg/ml) treatment restores leishmanicidal
effects in Sb
SLD- unlike Sb
RLD-infected DCs despite prolonged
infection. BMDCs were infected with 2001Pm (Sb
SLD) or 39Pm
(Sb
RLD) at a MOI of 10:1 for 24 hours. BMDCs were then
washed and treated with 200 nM Wort or 50 mM Ly for 1 hour.
Subsequently, BMDCs were stimulated with 20 or 40 mg/ml of
SAG for 24 hours or left untreated. The percentage of infected
BMDCs (A) and number of intracellular amastigotes per 1000
BMDCs (B) were determined by Giemsa staining. SAG20 and
SAG40 represent stimulation of BMDCs with 20 and 40 mg/ml of
SAG, respectively. Data are representative of three independent
experiments.
*p,0.005,
{p=0.094 and
#p= 0.13 versus
DC+2001Pm
**p,0.005 versus DC+2001Pm+SAG40 (Student’s t
test). Findings were considered significant with "p" values # 0.05.
Error bars indicate mean 6 SD.
Found at: doi:10.1371/journal.ppat.1000907.s010 (1.62 MB TIF)
Figure S11 Pretreatment with PI3K inhibitors block SAG-
induced NF-kB signaling in Sb
SLD-infected DCs. BMDCs were
infected for 3 hours with 2001Pm (Sb
SLD) and 39Pm (Sb
RLD) at
MOI 10:1, treated with Wort or Ly and stimulated with SAG (20
mg/ml) for indicated times as in Figure 8. (A) In vitro IKK activity
was measured as in Figure 3. The same blot was reprobed for
IKK1 and IKK2 protein. (B) Expression of cytoplasmic IkBa and
b-actin protein was detected by Western blot using the same blot.
(C) Nuclear NF-kB or OCT-1 DNA binding activity was
determined via EMSA. Data are representative of three
independent experiments.
Found at: doi:10.1371/journal.ppat.1000907.s011 (4.49 MB TIF)
Figure S12 LD cGCS heavy-chain (LD-cGCShc) expression is
more in Sb
RLD- compared to Sb
SLD-infected BMDCs. BMDCs
were infected with 2001Pm (Sb
SLD) or 39Pm (Sb
RLD) for 3 hours
at MOI 10:1. Infected DCs were then stimulated with SAG (20
mg/ml) for 3 hours or left untreated. The mRNA expression of
LD-cGCShc versus LD-tubulin was determined via RT-PCR.
Densitometric data represent ratio of intensity of LD-cGCShc to
LD-tubulin mRNA expression per unit area and are presented as
an arbitrary unit. Data are representative of three independent
experiments. Error bars indicate mean 6 SD.
Found at: doi:10.1371/journal.ppat.1000907.s012 (1.63 MB TIF)
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